- Written communication by the subject company relating to a third party tender offer (SC14D9C)
19 Octubre 2010 - 6:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE
SECURITIES EXCHANGE ACT OF 1934
CARDIAC SCIENCE CORPORATION
(Name of Subject Company)
CARDIAC SCIENCE CORPORATION
(Name of Person Filing Statement)
Common Stock, Par Value $0.001 Per Share
(Title of Class of Securities)
14141A108
(CUSIP Number of Class of Securities)
David L. Marver and Michael K. Matysik
Cardiac Science Corporation
3303 Monte Villa Parkway
Bothell, Washington 98021
(425) 402-2000
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications
on Behalf of the Person(s) Filing Statement)
With a copy to:
Stewart M. Landefeld, Esq. and Eric A. DeJong, Esq.
Perkins Coie LLP
1201 Third Avenue, Suite 4800
Seattle, Washington 98109
(206) 359-8000
þ
|
|
Check the box if the filing relates solely to preliminary communications made before the
commencement of a tender offer.
|
On October
19, 2010, Cardiac
Science Corporation
provided the following materials to employees of Cardiac
Science Corporation:
1
All Hands Meeting
October 19, 2010
|
What happened?
Signed an agreement to sell Cardiac Science to
Opto Circuits (India) Ltd.
$2.30/share
Approximately $55M total
Sale is not yet final
Tender Offer to launch within 10 business days
More than 60% outstanding shares must be tendered
Customary closing conditions must be met
Expected to finalize within 90 days
|
Why did we sell?
Despite excellent progress improving the company:
Revitalized product lines
Strengthened operations
Improved quality systems
We encountered a storm of events in 2009/2010:
Global economic recession
Loss of Japan AED distributor and revenue
Large AED recall
Weakened by this storm, we were increasingly limited:
Investing in business
Acquiring new technologies
Weathering new challenges that may arise
|
Who is Opto Circuits?
Headquarters in Bangalore, India
~750 employees
Public company: BSE (Bombay) and NSE
(National) Stock Exchanges in India
Market capitalization: US$1.3B
2010 revenue: US$243M (ending 3/31/10)
2010 EBITDA: US$81M (ending 3/31/10)
Key Geographies: North America, EU, Asia
Product lines: Vital Signs Monitors, Pulse
Oximetry Sensors, Anesthesia Respiratory
Care Equipment, PAD Diagnostic Equipment,
Angioplasty Stents and Balloons, Orthopedic
Implants, Catheters
Brands: Criticare, Unetixs, Mediaid, Eurocor,
Devon, Ormed
Revenue: India 12%, Rest of World 88%
|
Who is Opto Circuits?
Established in 1992
10-year CAGR of 49.68%
More than 100 types of medical devices; 17 clinical categories
across 12 medical fields
Addressable market of more than US $15 billion
Products sold in more than 100 countries
USFDA-listed noninvasive products
CE-marked invasive products
10 certified manufacturing facilities in Asia and North America
49 patents and 34 trademarks
Ranked by Forbes Asia as one amongst "200 Best Under a
Billion" companies in Asia Pacific (September 2009) for the
second consecutive time
|
Opto Circuits acquisitions
|
Opto Circuits awards
Business Standard - BS1000 Star SME (3/09)
Industry 2.0 - Ranked 11th in the 3rd SMB Awards (3/09)
Forbes Asia - 200 Best Under a Billion in AsiaPac (9/08)
Forbes Asia - 200 Best Under a Billion in AsiaPac (9/09)
|
Opto Circuits selling and
distribution
100 countries across four market segments
Distributors and direct sales forces in India (AMDL), Germany
(Eurocor) and the US (Criticare, Mediaid, and Unetixs)
Consumer reach through OEMs, distributors, GPOs, hospitals, doctors
|
Opto Circuits certifications
Meets world-class standards of ISO 9001 - 2000 and
ISO 13485-2003. Certified by UL; UKAS accredited.
Environmental management system standard certified
(ISO 14001: 2004)
Occupational Health and Safety Management System
Standard certified (OHSAS 18001:2007 by UL)
|
How Cardiac Science
will benefit
|
How will Cardiac Science
benefit?
CSC will become a subsidiary of Opto Circuits,
bringing:
Financial stability
Opportunities to expand
New technologies
Larger global salesforce footprint
Collaboration with other Opto Circuits businesses
Increased pricing flexibility
Less regulatory burden (SEC)
|
How will your job change?
No immediate changes to pay or benefits
expected
Opto Circuits has indicated it wants to learn
more about our business before making
changes
Opto Circuits has not otherwise
communicated their plans
|
If contacted...
Media Inquiries:
Joe Hage, Director of Marketing Communications
x 2074, jhage@cardiacscience.com
Investor Inquiries:
Matt Clawson, Allen & Caron, 949.474.4300,
matt@allencaron.com
Tender Offer Inquiries:
To be communicated in Tender Offer information from BNY Mellon
|
Important Additional
Information
The tender offer for the outstanding common stock of Cardiac Science Corporation (the
"Company") referred to in this document has not yet commenced. This document is neither an
offer to purchase nor a solicitation of an offer to sell any securities. The solicitation and the
offer to buy shares of the Company's common stock will be made pursuant to an offer to
purchase and related materials that Opto Circuits (India) Ltd. ("Opto Circuits") and a wholly-
owned subsidiary of Opto Circuits ("Merger Sub") intend file with the Securities and Exchange
Commission. At the time the offer is commenced Opto Circuits and Merger Sub will file a
tender offer statement on Schedule TO with the Securities and Exchange Commission, and
thereafter the Company will file a solicitation/recommendation statement on Schedule 14D-9
with respect to the offer. The tender offer statement (including an offer to purchase, a related
letter of transmittal and other offer documents) and the solicitation/recommendation
statement will contain important information that should be read carefully and considered
before any decision is made with respect to the tender offer. These materials will be sent free
of charge to all stockholders of the Company when available. In addition, all of these materials
(and all other materials filed by the Company with the Securities and Exchange Commission)
will be available at no charge from the Securities and Exchange Commission through its
website at www.sec.gov. Investors and security holders may also obtain free copies of the
tender offer documents, once available, from the information agent for the tender offer or from
the Company's Investor Relations at 949.474.4300.
|
Forward Looking Statements
This document contains forward-looking statements relating to the potential acquisition of
Cardiac Science Corporation by Opto Circuits, including the expected dates of closing of the
tender offer and merger and the potential benefits and consequences of the acquisition.
These are forward-looking statements for purposes of the safe harbor provisions under the
Private Securities Litigation Reform Act of 1995. The actual results of the acquisition could
vary materially as a result of a number of factors, including: uncertainties as to how many of
Cardiac Science Corporation's stockholders will tender their stock in the tender offer; the
possibility that competing offers will be made; and the possibility that various closing
conditions for the transaction may not be satisfied or waived. Other factors that may cause
actual results to differ materially include those set forth in the reports that we file from time
to time with the Securities and Exchange Commission, including our annual report on Form
10-K for the year ended December 31, 2009 and quarterly and current reports on Form 10-Q
and 8-K. These forward-looking statements reflect Cardiac Science Corporation's expectations
as of the date of this document. Cardiac Science Corporation undertakes no obligation to
update the information provided herein.
|
21
CardiacScience.com
3308 Monte Villa Parkway
Bothell, WA 98021
425.402.2000
800.426.0337
(c) 2010, Cardiac Science Corporation. All rights reserved.
No part of this work may be reproduced in any form without written permission from Cardiac Science.
|
Cardiac Science Corp (MM) (NASDAQ:CSCX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Cardiac Science Corp (MM) (NASDAQ:CSCX)
Gráfica de Acción Histórica
De May 2023 a May 2024
Real-Time news about Cardiac Science Corp (MM) (NASDAQ): 0 recent articles
Más de Artículos de Noticias